Quantcast

Flood Law Group to Sponsor BenicarLawsuits.org

July 26, 2013

The personal injury lawyers at Flood Law Group announce the release of the new website, BenicarLawsuits.org, an online resource dedicated to educating consumers about the risks associated with the drug Benicar.

(PRWEB) July 26, 2013

Flood Law Group, a national personal injury law firm with extensive experience in pharmaceutical product liability litigation, sponsors the site BenicarLawsuits.org, an online resource created to help consumers learn about the risks associated with the blood pressure medication Benicar (olmesartan medoxomil).

On July 3, 2013, the Food and Drug Administration (FDA) approved changes to the high blood pressure medication Benicar to reflect a risk for a gastrointestinal side effect known as sprue-like enteropathy.*

Sprue-like enteropathy is a condition with symptoms similar to those experienced by individuals with celiac disease, including:

  •     Chronic diarrhea
  •     Extreme weight loss
  •     Nausea and vomiting
  •     Intestinal inflammation
  •     Abnormal electrolyte levels

Individuals with Benicar-induced sprue-like enteropathy experienced a total cessation of symptoms when they stopped taking this medication, according to the FDA.*

Benicar, also marketed as Benicar HTC, Azor, Tribenzor, and generics, is one of eight drugs belonging to the angiotensin II receptor blocker (ARB) family of high blood pressure medications. No other ARB drugs have been linked to sprue-like enteropathy.

According to the Flood Law Group, individuals who have developed sprue-like enteropathy while taking Benicar may be entitled to financial compensation for medical bills and other damages. If you or a loved one has suffered severe gastrointestinal side effects after using Benicar, you can learn more about your potential right to compensation by contacting the Flood Law Group.

*http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm

For the original version on PRWeb visit: http://www.prweb.com/releases/benicar-lawsuits/website/prweb10966557.htm


Source: prweb



comments powered by Disqus